Johnson & Johnson Archives - Page 20 of 33

Janssen COVID-19 booster leads to nine-fold increase in neutralizing antibodies

Johnson & Johnson (NYSE:JNJ) has announced that a booster of its viral-vector COVID-19 vaccine led to considerable increases in coronavirus spike-binding antibodies, according to interim data from two Phase 1/2 trials known as VAC31518COV1001 and VAC31518COV2001.

In particular, the boosters led to a nine-fold increase in antibodies relative to levels 28 days after administering the prime dose.

Janssen noted robust increases in participants aged 18 to 55 and those 65 and older who received a reduced booster dose.

Get the full story from our sister site, Drug Discovery & Development.

Janssen COVID-19 booster leads to nine-fold increase in neutralizing antibodies

Johnson & Johnson (NYSE:JNJ) has announced that a booster of its viral-vector COVID-19 vaccine led to considerable increases in coronavirus spike-binding antibodies, according to interim data from two Phase 1/2 trials known as VAC31518COV1001 and VAC31518COV2001.

In particular, the boosters led to a nine-fold increase in antibodies relative to levels 28 days after administering the prime dose.

Janssen noted robust increases in participants aged 18 to 55 and those 65 and older who received a reduced booster dose.

The company has submitted the data to the pre-print publisher medRxiv.

Johnson & Johnson had found earlier that the Ad26.COV2.S vaccine elicited significant protection against COVID-19 eight months after the initial vaccination. Those data were published in NEJM.

CDC said on August 18 that recipients of the Johnson & Johnson vaccine will likely benefit from a booster, but that more data are required.

The company i…

MedTech 100 roundup: On the rise again

After a slight hiccup disrupted weeks of improvement, the medtech industry again flexed its muscles over the last seven days.

MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (Aug. 20) at 119.63 points, representing a 1.5% rise from the 117.92-point tally set a week prior.

The shift marks a quick rebound from the -1.2% dip observed in the previous week and the index now sits at its highest week-ending mark ever, having actually hit an all-time best of 119.72 points on Aug. 17.

Medtech’s performance continues to reflect an overall rebound from the struggles brought on by the COVID-19 pandemic, too. The industry remains well above the marks set around the height of the pandemic, having registered a 29.6% increase from the pre-pandemic high of 92.32 (set on Feb. 19, 2020). Moreover, it remains well ahead of the mid-pandemic low of 62.13 (March 23, 2020) as well, totaling an 92.5% asc…

J&J’s Gorsky to step down as CEO

Citing “family health reasons,” Johnson & Johnson’s Alex Gorsky will hand the CEO role over to Joaquin Duato, current vice-chair of the company’s executive committee, at the start of the new year.

Gorsky oversaw a near-decade of significant growth at the medtech and pharma giant. His tenure ultimately will be capped off by Johnson & Johnson’s development of a single-shot vaccine for COVID-19, an alternative to the dominant two-shot mRNA-based vaccines.

Get the full story on our sister site MassDevice.

J&J’s Gorsky to step down as CEO

Citing “family health reasons” Johnson & Johnson’s Alex Gorsky will hand the CEO role over to Joaquin Duato, current vice chairman of the company’s executive committee, at the start of the new year.

Gorsky oversaw a near decade of significant growth by the company. His tenure ultimately will be capped off by Johnson & Johnson’s development of a single-shot vaccine for COVID-19, an alternative to the dominant two-shot mRNA-based vaccines.

“The decision to step aside was one of the most difficult of my career,” Gorsky said in a release issued Thursday. “This is the right time for the Company as our organization is delivering strong performance across all three segments and is positioned for continued success, in addition to this being the right time for me personally as I focus more on my family due to family health reasons.”

Gorsky was name chairman and CEO in 2012. Next year, he’ll assume the executive chairman role, positioning him t…

Depuy Synthes launches Inhance shoulder system

Johnson & Johnson’s (NYSE:JNJ) Depuy Synthes this week announced that it has launched its Inhance should system.

Raynham, Mass.-based Depuy Synthes designed the Inhance system as a fully integrated shoulder arthroplasty system. It has an intuitive stemless-first surgical approach that offers surgeons the ability to seamlessly transition from stemless to stemmed implants during surgical procedures, according to the company.

“Advancements in shoulder arthroplasty have enabled a broader range of surgical treatment over the past decade but have increased the complexity and cost of preparing for each surgical case,” J. Michael Wiater, vice chairman and chief of shoulder surgery at Oakland University William Beaumont School of Medicine, said in a news release. “The Inhance Shoulder System can empower surgeons to seamlessly alter their surgical flow, while simultaneously keeping their focus on the patient, and has the potential to reduce OR time.”

The…

Canada to donate 10 million J&J vaccine doses to developing countries

Initially facing a shortage of COVID-19 vaccines, Canada has now vaccinated a greater share of its population than the U.S.

Now, the country is planning on donating 10 million doses to low- and middle-income countries via the COVAX initiative, a global program that aims to distribute vaccines in developing nations.

The country had faced controversy earlier this year for tapping into a supply of vaccines initially set aside for COVAX.

The Africa Center for Disease Control (AfricaCDC) recently announced that it had chosen the Johnson & Johnson COVID-19 vaccine. The vaccine has the advantage of having straightforward storage requirements and is available as a single dose.

To date, Canada has committed 40 million doses to the COVAX program and additional financial support for the initiative.

In June, Canada rejected some 300,000 doses of U.S.-made Janssen vaccine over potential contamination problems.

MedTech 100 roundup: Return to normal after last week’s spike

After rising more than 31 points to heights never before reached, the medtech industry returned to normal this past week.

MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (July 23) at 115.54 points, a total that, had it not been for last week, would be the index’s all-time high.

However, the index finished the previous week (July 16) at 145.88 points, a remarkable 27.1% rise week-over-week, registering by far the greatest increase the index has seen since its inception — and perhaps an anomaly. Although the index slid by -20.8%, it remains in a stronger position than ever before, last week notwithstanding.

Medtech’s performance continues to reflect an overall rebound from the struggles brought on by the COVID-19 pandemic, too. The industry has registered a 25.2% increase from the pre-pandemic high of 92.32 (set on Feb. 19, 2020). It remains well ahead of the mid-pandemic low…

Johnson & Johnson, other companies to pay $26B over opioid crisis

California Attorney General Rob Bonta announced a $26 billion settlement with Johnson & Johnson, among other companies, over opioids.

The settlement includes Johnson & Johnson, who manufactured and marketed opioids, along with pharmaceutical distributors Cardinal, McKesson and AmerisourceBergen.

Get the full story at our sister site, Pharmaceutical Processing World.

Johnson & Johnson, other companies to pay $26B over opioid crisis

California Attorney General Rob Bonta announced a $26 billion settlement with Johnson & Johnson, among other companies, over opioids.

The settlement includes Johnson & Johnson, who manufactured and marketed opioids, along with pharmaceutical distributors Cardinal, McKesson and AmerisourceBergen.

According to a news release, the settlement resolves investigations and litigation over the companies’ roles in creating and fueling the opioid epidemic while requiring significant industry changes to prevent such a crisis from repeating itself.

“Nothing can undo the devastating loss of life caused by the opioid epidemic, or stop the grief it has caused for its victims and their families, but this proposed settlement represents one step in the process of healing our communities,” Bonta said in the release. “Along with our coalition partners, our office has worked to hold accountable bad actors who fueled this public health crisis …

J&J beats The Street in Q2, raises guidance

An accelerated rebound in medical device sales helped drive Johnson & Johnson (NYSE:JNJ) second-quarter results that topped the consensus forecast.

The New Brunswick, N.J.-based company posted profits of $6.3 billion, or $2.35 per share, on sales of $23.3 billion for the three months ended June 30, 2021, for a 73.1% bottom-line gain on sales growth of 27.1% year-over-year.

Get the full story at our sister site, MassDevice.

J&J rises before hours on Street-beating Q2, raised guidance

Johnson & Johnson (NYSE:JNJ) shares ticked up before the market opened today on second-quarter results that topped the consensus forecast.

The New Brunswick, N.J.-based company posted profits of $6.3 billion, or $2.35 per share, on sales of $23.3 billion for the three months ended June 30, 2021, for a 73.1% bottom-line gain on sales growth of 27.1% year-over-year.

Adjusted to exclude one-time items, earnings per share were $2.48, 21¢ ahead of Wall Street, where analysts were looking for sales of $22.2 billion.

Johnson & Johnson saw the largest revenue increase in its medical device sales, with 57.8% growth attributed mainly to the market’s recovery from the COVID-19 pandemic this time a year ago and the uptick in procedures after many were deferred during the pandemic.

Additionally, the company saw 14.1% growth in its pharmaceutical arm and 10% growth in consumer health.

“Our second-quarter results showcase Johnson &…